

# Jörg Hense

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9421389/publications.pdf>

Version: 2024-02-01

14  
papers

502  
citations

1162367

8  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

769  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Short and Long Survival after Surgery for Breast Cancer Brain Metastases. <i>Cancers</i> , 2022, 14, 1437.	1.7	1
2	Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery. <i>Journal of Neuro-Oncology</i> , 2022, 159, 53-63.	1.4	4
3	Changes in fatigue, barriers, and predictors towards physical activity in advanced cancer patients over a period of 12 monthsâ€”a comparative study. <i>Supportive Care in Cancer</i> , 2021, 29, 5127-5137.	1.0	3
4	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468.	13.7	232
5	HER2 Receptor Conversion Is a strong Survival Predictor in Patients with Breast Cancer Brain Metastases. <i>World Neurosurgery</i> , 2021, 152, e332-e343.	0.7	4
6	Improved survival in metastatic breast cancer: results from a 20-year study involving 1033 women treated at a single comprehensive cancer center. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1559-1566.	1.2	12
7	Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients. <i>BMC Palliative Care</i> , 2020, 19, 43.	0.8	54
8	Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell Lymphomas. <i>Oncology Research and Treatment</i> , 2019, 42, 580-588.	0.8	4
9	MET Expression in Advanced Nonâ€”Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	1.1	61
10	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2001-2001.	0.8	21
11	High Prevalence of Concomitant Oncogene MutationsÄin Prospectively Identified Patients withÄROS1-Positive Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 54-64.	0.5	62
12	Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 81-88.	1.1	3
13	Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. <i>European Journal of Cancer</i> , 2013, 49, 3076-3082.	1.3	26
14	S2k Kurzleitlinie â€” Merkelzellkarzinom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 31-38.	0.4	15